Skip to main content
a b c d e f g h i j k l m n o p q r s t u v w x y z #

Toxicology

Promethazine

Promethazine

High dose therapeutic use of promethazine associated with concentrations of up to 0.2 mg/L. Toxicity associated with concentrations > 1 mg/L.  (Schulz et al. Critical Care 2012, 16:R136).

Propranolol

Propranolol

Therapeutic range: 0.02 - 0.3 mg/L.  Toxicity associated with concentrations > 1.0 mg/L.  (Schulz et al. Critical Care 2012, 16:R136). 

Quetiapine

Quetiapine

Therapeutic range: 100 - 500 μg/L. Toxicity associated with concentrations >1000 μg/L. (Schulz et al. Critical Care 2012, 16:R136).

Risperidone

Risperidone

Therapeutic concentrations of risperidone range between 10 and 90 μg/L, and the total sum of risperidone and 9-hydroxyrisperidone range between 10 and 100 μg/L.

Risperidone

Risperidone

Therapeutic concentrations of risperidone range between 10 and 90 μg/L, and the total sum of risperidone and 9-hydroxyrisperidone range between 10 and 100 μg/L.

Selenium

Selenium

 

 

Selenium (SEL)

µmol/L

< 18 months

0.33-0.97

18 m – 3 years

0.51-1.12

4 years – 18 years

0.6-1.29

19 years to 64 years

0.75-1.46

> 64 years

0.66-1.57

(Source: SAS Trace Element Update, 2018)

Sertraline

Sertraline

Therapeutic range: 10 -150 ug/L

Sildenafil

Sildenafil

0.05 - 0.5 mg/L

Sildenafil

Sildenafil

0.05 - 0.5 mg/L

Sulphonylurea Screen (Sulfonylurea Screen)

Sulphonylurea Screen (Sulfonylurea Screen)

This is a screening test for the presence of sulphonylureas in plasma or urine. As such, we will report results as Positive or Negative for the drugs listed above. All can be detected reliably at concentrations of 0.5 mg/L in urine and plasma.

Synthetic Cannabinoid Receptor Agonist (SCRA) Screen

Synthetic Cannabinoid Receptor Agonist (SCRA) Screen

This is a screening test. Drugs detected in specimens will be stated on the report.

THIS ASSAY IS CURRENTLY NOT AVAILABLE

Synthetic Cannabinoid Receptor Agonist (SCRA) Screen

Synthetic Cannabinoid Receptor Agonist (SCRA) Screen

This is a screening test. Drugs detected in specimens will be stated on the report.

THIS ASSAY IS CURRENTLY NOT AVAILABLE

Teriflunomide (A77 1726, leflunomide metabolite)

Teriflunomide (A77 1726, leflunomide metabolite)

Therapeutic targets remain only loosely defined and appear to vary depending on the purpose of therapy. A reference range of 18 - 63 mg/L has been suggested. Adverse reactions to leflunomide do not correlate well with serum drug concentration, but include diarrhoea, hypertension, and liver toxicity. 

Please contact the laboratory for more information.

Teriflunomide (A77 1726, leflunomide metabolite)

Teriflunomide (A77 1726, leflunomide metabolite)

Therapeutic targets remain only loosely defined and appear to vary depending on the purpose of therapy. A reference range of 18 - 63 mg/L has been suggested. Adverse reactions to leflunomide do not correlate well with serum drug concentration, but include diarrhoea, hypertension, and liver toxicity. 

Please contact the laboratory for more information.

Toxicology Screen (Urine & Serum)

Toxicology Screen (Urine & Serum)

A toxicology screen is qualitative result and as such, an interpretative report will be issued.

Tramadol

Tramadol

High dose therapeutic use of tramadol associated with concentrations of up to 0.8 mg/L. Toxicity associated with concentrations > 1 mg/L.  (Schulz et al. Critical Care 2012, 16:R136).

 

Trazodone

Trazodone

Therapeutic range: 0.70 -1.0 mg/L. Toxicity associated with concentrations > 1.2 mg/L. (Schulz et al. Critical Care 2012, 16:R136). 

However, tolerance for the drug varies greatly between indiciduals. Please contact the laboratory for interpretation.  

 

Urinary Antihypertensive Drug Screen

Urinary Antihypertensive Drug Screen

This is a screening tests. Drugs detected in specimens will be stated on the report.

Urinary Antihypertensive Drug Screen

Urinary Antihypertensive Drug Screen

This is a screening tests. Drugs detected in specimens will be stated on the report.

Urine Copper

Urine Copper

Reference Ranges (pre-chelation)

Normal excretion usually <0.8 umol/24 hours.
Cholestasis, hepatic cirrhosis, covert Wilson's Disease >0.8 umol/24 hours
Patients with frank Wilson's Disease or acute hepatic crisis >1.6 umol/24 hours

(Source: SAS Trace Element Analysis, 4th Edition, 2006).

 

<<  1 2 3 [45  >>